SCHEMBL3454682

SCHEMBL3454682

O=c1[nH]c2nccc(Cl)c2c2cc(C(F)(F)F)ccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.63
AURKB Q96GD4 2/20 0.63
JUN P05412 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
DAO P14920 1/20 0.44
TNKS O95271 1/20 0.43
KIF11 P52732 3/20 0.43
PARP1 P09874 1/20 0.43
PTK6 Q13882 1/20 0.42
CHUK O15111 1/20 0.42
HSD17B10 Q99714 1/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3B P49841 1/20 0.41
CDK5 Q00535 1/20 0.41
CDK5R1 Q15078 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6523418 0.83 AURKA (0.67) AURKAAURKBDAOPARP1PTK6
SCHEMBL6517191 0.83 AURKA (0.70) AURKAAURKBDAOPARP1PTK6
SCHEMBL679019 0.78 AURKA (1.00) AURKAAURKBDAOPARP1
SCHEMBL6521696 0.78 AURKA (0.67) AURKAAURKBDAOPARP1PTK6
SCHEMBL6522132 0.77 AURKA (0.62) AURKAAURKBDAOPARP1
SCHEMBL6519310 0.77 AURKA (0.70) AURKAAURKBDAOPARP1PTK6
SCHEMBL6521579 0.75 AURKA (0.67) AURKAAURKBDAOPARP1PTK6
SCHEMBL6524053 0.74 AURKA (0.58) AURKAAURKBDAOKIF11PARP1
SCHEMBL6527216 0.74 AURKA (0.61) AURKAAURKBDAOPTK6
SCHEMBL3455180 0.72 AURKA (0.81) AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
EP-2254889-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF Merck Patent GmbH (DE) 2010-12-01 EP disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 AURKA 538/4885AURKB 487/4885JUN 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.